TRIM33 is altered in 0.13% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, bladder urothelial carcinoma, high grade ovarian serous adenocarcinoma, and thyroid gland papillary carcinoma having the greatest prevalence of alterations .
The most common alterations in TRIM33 are TRIM33-RET Fusion (0.10%), TRIM33 K5T (1.05%), TRIM33-ERBB4 Fusion (0.02%), TRIM33 K5Q (0.77%), and TRIM33 M1? (0.77%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.